Cargando…
Toward a new ‘EPOCH’: optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction
Despite the marked adverse impacts of erectile dysfunction (ED) on quality of life and well-being, many patients (and/or their partners) do not seek medical attention for this problem, do not receive treatment or discontinue such treatment even when it has effectively restored erectile responses to...
Autores principales: | Sadovsky, R, Brock, G B, Gutkin, S W, Sorsaburu, S |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2779984/ https://www.ncbi.nlm.nih.gov/pubmed/19624789 http://dx.doi.org/10.1111/j.1742-1241.2009.02119.x |
Ejemplares similares
-
Oral L-citrulline and Transresveratrol Supplementation Improves Erectile Function in Men With Phosphodiesterase 5 Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Crossover Pilot Study
por: Shirai, Masato, et al.
Publicado: (2018) -
Quality of Information in YouTube Videos on Erectile Dysfunction
por: Fode, Mikkel, et al.
Publicado: (2020) -
Erectile Dysfunction is Predictive Symptom for Poor Semen in Newlywed Men in Japan
por: Tsujimura, Akira, et al.
Publicado: (2019) -
Influence of Alcohol on Phosphodiesterase 5 inhibitors Use in Middle- to Old-Aged Men: A Comparative Study of Adverse Events
por: Kim, Jong Nyeong, et al.
Publicado: (2019) -
Deterioration of Chronotropic Responses and Heart Rate Recovery Indices in Men With Erectile Dysfunction
por: Kucukdurmaz, Faruk, et al.
Publicado: (2017)